Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes

Microbes and Infection

Volumn 8, Issue 6, 2006, Pages 1424-1433

  Zipeto, Donato ^a   Matucci, Andrea ^a,b   Ripamonti, Chiara ^c   Scarlatti, Gabriella ^c   Rossolillo, Paola ^a   Turci, Marco ^a   Sartoris, Silvia ^b   Tridente, Giuseppe ^b   Bertazzoni, Umberto ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Section of Hematology   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Fusion complex; Membrane fusion; Neutralizing antibodies

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLUTARALDEHYDE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MEMBRANE FUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; TEMPERATURE;

ANIMALS; ANTIGENS, CD4; CELL FUSION; CHO CELLS; CRICETINAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; NIH 3T3 CELLS; RECEPTORS, CCR5; RECOMBINANT FUSION PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745250516     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2006.03.001     Document Type: Article

References (47)

1. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., and Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 (1984) 763-767
2. Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312 (1984) 767-768
3. Doms R.W., and Peiper S.C. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235 (1997) 179-190
4. Doms R.W., and Moore J.P. HIV-1 membrane fusion: targets of opportunity. J. Cell. Biol. 151 (2000) F9-F14
5. Melikyan G.B., Markosyan R.M., Hemmati H., Delmedico M.K., Lambert D.M., and Cohen F.S. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell. Biol. 151 (2000) 413-423
6. Kliger Y., Peisajovich S.G., Blumenthal R., and Shai Y. Membrane-induced conformational change during the activation of HIV-1 gp41. J. Mol. Biol. 301 (2000) 905-914
7. Mascola J.R. Defining the protective antibody response for HIV-1. Curr. Mol. Med 3 (2003) 209-216
8. Reitter J.N., Means R.E., and Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat. Med 4 (1998) 679-684
9. Hoffman T.L., LaBranche C.C., Zhang W., Canziani G., Robinson J., Chaiken I., et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 6359-6364
10. Sanders R.W., Schiffner L., Master A., Kajumo F., Guo Y., Dragic T., et al. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J. Virol 74 (2000) 5091-5100
11. Lu S., Wyatt R., Richmond J.F., Mustafa F., Wang S., Weng J., et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res. Hum. Retroviruses 14 (1998) 151-155
12. Cao J., Sullivan N., Desjardin E., Parolin C., Robinson J., Wyatt R., et al. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol 71 (1997) 9808-9812
13. Parren P.W., Moore J.P., Burton D.R., and Sattentau Q.J. The neutralizing antibody response to HIV-1: viral evasion and escape from humsoral immunity. AIDS 13 Suppl. A (1999) S137-S162
14. Moore J.P., Parren P.W., and Burton D.R. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J. Virol 75 (2001) 5721-5729
15. Chow Y.H., Wei O.L., Phogat S., Sidorov I.A., Fouts T.R., Broder C.C., et al. Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens. Biochemistry 41 (2002) 7176-7182
16. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X., Binley J.M., et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 6913-6918
17. Xiao X., Phogat S., Shu Y., Phogat A., Chow Y.H., Wei O.L., et al. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity. Vaccine 21 (2003) 4275-4284
18. Finnegan C.M., Berg W., Lewis G.K., and DeVico A.L. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J. Virol 75 (2001) 11096-11105
19. Finnegan C.M., Berg W., Lewis G.K., and DeVico A.L. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J. Virol 76 (2002) 12123-12134
20. Fouts T., Godfrey K., Bobb K., Montefiori D., Hanson C.V., Kalyanaraman V.S., et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11842-11847
21. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol 75 (2001) 10892-10905
22. DeVico A.L., Rahman R., Welch J., Crowley R., Lusso P., Sarngadharan M.G., et al. Monoclonal antibodies raised against covalently crosslinked complexes of human immunodeficiency virus type 1 gp120 and CD4 receptor identify a novel complex-dependent epitope on gp 120. Virology 211 (1995) 583-588
23. Giannecchini S., Del Mauro D., Matteucci D., and Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies. J. Virol 75 (2001) 4424-4429
24. LaCasse R.A., Follis K.E., Trahey M., Scarborough J.D., Littman D.R., and Nunberg J.H. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 283 (1999) 357-362
25. Verschoor E.J., van Vliet A.L., Egberink H.F., Hesselink W., van Alphen W.E., Joosten I., et al. Vaccination against feline immunodeficiency virus using fixed infected cells. Vet. Immunol. Immunopathol 46 (1995) 139-149
26. Yamamoto J.K., Okuda T., Ackley C.D., Louie H., Pembroke E., Zochlinski H., et al. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res. Hum. Retroviruses 7 (1991) 911-922
27. Markosyan R.M., Cohen F.S., and Melikyan G.B. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol. Biol. Cell. 14 (2003) 926-938
28. Sullivan N., Sun Y., Sattentau Q., Thali M., Wu D., Denisova G., et al. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol 72 (1998) 4694-4703
29. Doranz B.J., Baik S.S., and Doms R.W. Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events. J. Virol 73 (1999) 10346-10358
30. Golding H., Zaitseva M., de Rosny E., King L.R., Manischewitz J., Sidorov I., et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Virol 76 (2002) 6780-6790
31. Gao F., Morrison S.G., Robertson D.L., Thornton C.L., Craig S., Karlsson G., et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID networks for HIV isolation and characterization. J. Virol 70 (1996) 1651-1667
32. Chanda P.K., Natuk R.J., Mason B.B., Bhat B.M., Greenberg L., Dheer S.K., et al. High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants. Virology 175 (1990) 535-547
33. Devesa F., Chams V., Dinadayala P., Stella A., Ragas A., Auboiroux H., et al. Functional reconstitution of the HIV receptors CCR5 and CD4 in liposomes. Eur. J. Biochem 269 (2002) 5163-5174
34. Deng H.K., Unutmaz D., KewalRamani V.N., and Littman D.R. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388 (1997) 296-300
35. Palermo D.P., DeGraaf M.E., Marotti K.R., Rehberg E., and Post L.E. Production of analytical quantities of recombinant proteins in Chinese hamster ovary cells using sodium butyrate to elevate gene expression. J. Biotechnol 19 (1991) 35-47
36. White J., Matlin K., and Helenius A. Cell fusion by Semliki Forest, influenza, and vesicular stomatitis viruses. J. Cell. Biol. 89 (1981) 674-679
37. Nunberg J.H., Follis K.E., Trahey M., and LaCasse R.A. Turning a corner on HIV neutralization?. Microbes Infect 2 (2000) 213-221
38. Gilljam G. Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses. AIDS. Res. Hum. Retroviruses 9 (1993) 431-438
39. Burrer R., Salmon-Ceron D., Richert S., Pancino G., Spiridon G., Haessig S., et al. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients. J. Virol 75 (2001) 5421-5424
40. Fouts T.R., Tuskan R., Godfrey K., Reitz M., Hone D., Lewis G.K., et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J. Virol 74 (2000) 11427-11436
41. Scarlatti G., Tresoldi E., Bjorndal A., Fredriksson R., Colognesi C., Deng H.K., et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med 3 (1997) 1259-1265
42. Scarlatti G., Albert J., Rossi P., Hodara V., Biraghi P., Muggiasca L., et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J. Infect. Dis 168 (1993) 207-210
43. Nunberg J.H. Retraction. Science 296 (2002) 1025
44. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med 6 (2000) 207-210
45. Gershoni J.M., Denisova G., Raviv D., Smorodinsky N.I., and Buyaner D. HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB J 7 (1993) 1185-1187
46. Oggioni M.R., Medaglini D., Romano L., Peruzzi F., Maggi T., Lozzi L., et al. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. AIDS Res. Hum. Retroviruses 15 (1999) 451-459
47. Jeffs S.A., Shotton C., Balfe P., and McKeating J.A. Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J. Gen. Virol 83 (2002) 2723-2732